EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Factors for progressive pulmonary fibrosis in connective tissue disease-related interstitial lung disease

Kyuhwan Kim iD, Jongmin Lee, Yong Suk Jo iD

Therapeutic Advances in Respiratory Disease · 2023-01 · 17

DOI: 10.1177/17534666231212301 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Respiratory Disease, online erschienen am 22.11.2023. Verfasst von Kyuhwan Kim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic Unive…. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Connective Tissue Diseases, Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Progressive fibrosis can occur in connective tissue disease (CTD)-related interstitial lung disease (ILD) and make the prognosis worse.

Objectives

This study aimed to investigate factors related to progressive pulmonary fibrosis (PPF) phenotype in CTD-ILDs.

Design

Medical records of patients diagnosed as CTD and ILD at a single, tertiary hospital in South Korea were retrospectively reviewed.

Methods

Patients whose lung functions were followed up for more than a year were included in analysis. PPF was defined as forced vital capacity (FVC) declined ⩾10% or diffusion capacity of carbon monoxide (DLco) ⩾15%.

Results

Of 110 patients with CTD-ILD, 24.5% progressed into PPF. Rheumatoid arthritis (RA) and Sjogren’s disease accounted for more than 63% of PPF. Compositions of CTD type were similar between PPF and non-PPF. Clinical characteristics and proportion of usual interstitial pneumonia (UIP) pattern on chest images were also similar between PPF and non-PPF. Approximately 10% of patients in both groups were treated with anti-fibrotic agents. Use of systemic steroids and/or other immunomodulating agents lowered the risk of developing PPF in CTD-ILD patients after adjusting for gender-age-physiology score and smoking status (adjusted odds ratio: 0.25, 95% confidence interval: 0.07–0.85).

Conclusion

About a quarter of CTD-ILD progressed into PPF. The use of immunomodulating agents lowered the risk of developing PPF. To improve outcomes of patients, future studies need to detect patients at higher risk for PPF earlier and set up clinical guidelines for treatment strategies in the process of PPF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung Diseases, InterstitialConnective Tissue DiseasesIdiopathic Pulmonary FibrosisHumansRetrospective StudiesImmunomodulating AgentsLung

Stichwörter der Autor:innen

connective tissue diseaseinterstitial lung diseaseprogressive fibrosisrisk factors

Substanzen

Immunomodulating Agents

Autor:innen und Institutionen

  • Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

ORCID-Profile: Kyuhwan Kim, Yong Suk Jo

Zitieren

APA

Kim, K., Lee, J., & Jo, Y. S. (2023). Factors for progressive pulmonary fibrosis in connective tissue disease-related interstitial lung disease. Therapeutic Advances in Respiratory Disease, 17. https://doi.org/10.1177/17534666231212301

Vancouver

Kim K, Lee J, Jo YS. Factors for progressive pulmonary fibrosis in connective tissue disease-related interstitial lung disease. Therapeutic Advances in Respiratory Disease. 2023;17. doi:10.1177/17534666231212301

BibTeX
@article{Kim2023,
  author = {Kim, Kyuhwan and Lee, Jongmin and Jo, Yong Suk},
  title = {Factors for progressive pulmonary fibrosis in connective tissue disease-related interstitial lung disease},
  journal = {Therapeutic Advances in Respiratory Disease},
  year = {2023},
  volume = {17},
  doi = {10.1177/17534666231212301}
}
Kostenlos starten →